- Home
- WRN vs ASMB Comparison
WRN vs ASMB Comparison
Compare WRN & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRN
- ASMB
- Stock Information
- Founded
- WRN 2006
- ASMB 2005
- Country
- WRN Canada
- ASMB United States
- Employees
- WRN N/A
- ASMB N/A
- Industry
- WRN Metal Mining
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- WRN Basic Materials
- ASMB Health Care
- Exchange
- WRN Nasdaq
- ASMB Nasdaq
- Market Cap
- WRN 248.0M
- ASMB 198.6M
- IPO Year
- WRN N/A
- ASMB 2010
- Fundamental
- Price
- WRN $1.52
- ASMB $23.82
- Analyst Decision
- WRN Strong Buy
- ASMB Strong Buy
- Analyst Count
- WRN 1
- ASMB 4
- Target Price
- WRN $4.00
- ASMB $38.67
- AVG Volume (30 Days)
- WRN 506.2K
- ASMB 174.5K
- Earning Date
- WRN 11-06-2025
- ASMB 11-06-2025
- Dividend Yield
- WRN N/A
- ASMB N/A
- EPS Growth
- WRN N/A
- ASMB N/A
- EPS
- WRN N/A
- ASMB N/A
- Revenue
- WRN N/A
- ASMB $33,247,000.00
- Revenue This Year
- WRN N/A
- ASMB $12.44
- Revenue Next Year
- WRN N/A
- ASMB N/A
- P/E Ratio
- WRN N/A
- ASMB N/A
- Revenue Growth
- WRN N/A
- ASMB 54.77
- 52 Week Low
- WRN $0.90
- ASMB $7.75
- 52 Week High
- WRN $1.58
- ASMB $27.17
- Technical
- Relative Strength Index (RSI)
- WRN 69.78
- ASMB 52.32
- Support Level
- WRN $1.45
- ASMB $22.50
- Resistance Level
- WRN $1.58
- ASMB $26.14
- Average True Range (ATR)
- WRN 0.06
- ASMB 1.09
- MACD
- WRN 0.02
- ASMB -0.52
- Stochastic Oscillator
- WRN 81.43
- ASMB 28.16
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.